Renal transplantation

Paul D. King, Cobi Lidor, Thomas P. Vail, Manikkam Suthanthiran, Terry B. Strom

Research output: Contribution to journalLetter

3 Citations (Scopus)

Abstract

Suthanthiran and Strom (Aug. 11 issue)1 “discourage the use of organs from donors seropositive for the hepatitis C virus [HCV] for grafting in recipients who are seronegative for the virus.” In the setting of renal transplantation, in which effective alternative renal-replacement therapy is available, this guideline is not adequate to prevent HCV infection and thus exposes patients to unacceptable risks. The authors' figure of 5 percent for the prevalence of chronic hepatitis due to HCV after kidney transplantation is optimistically low. Lau et al. found that among 100 patients undergoing kidney transplantation, 18 were seropositive for HCV.  . .

Original languageEnglish
Pages (from-to)1719-1720
Number of pages2
JournalNew England Journal of Medicine
Volume331
Issue number25
DOIs
Publication statusPublished - 22 Dec 1994
Externally publishedYes

Fingerprint

Hepacivirus
Kidney Transplantation
Renal Replacement Therapy
Virus Diseases
Chronic Hepatitis
Complementary Therapies
Tissue Donors
Guidelines
Viruses

ASJC Scopus subject areas

  • Medicine(all)

Cite this

King, P. D., Lidor, C., Vail, T. P., Suthanthiran, M., & Strom, T. B. (1994). Renal transplantation. New England Journal of Medicine, 331(25), 1719-1720. https://doi.org/10.1056/NEJM199412223312514

Renal transplantation. / King, Paul D.; Lidor, Cobi; Vail, Thomas P.; Suthanthiran, Manikkam; Strom, Terry B.

In: New England Journal of Medicine, Vol. 331, No. 25, 22.12.1994, p. 1719-1720.

Research output: Contribution to journalLetter

King, PD, Lidor, C, Vail, TP, Suthanthiran, M & Strom, TB 1994, 'Renal transplantation', New England Journal of Medicine, vol. 331, no. 25, pp. 1719-1720. https://doi.org/10.1056/NEJM199412223312514
King, Paul D. ; Lidor, Cobi ; Vail, Thomas P. ; Suthanthiran, Manikkam ; Strom, Terry B. / Renal transplantation. In: New England Journal of Medicine. 1994 ; Vol. 331, No. 25. pp. 1719-1720.
@article{4861efd9435a40c69e3f4ce84488294e,
title = "Renal transplantation",
abstract = "Suthanthiran and Strom (Aug. 11 issue)1 “discourage the use of organs from donors seropositive for the hepatitis C virus [HCV] for grafting in recipients who are seronegative for the virus.” In the setting of renal transplantation, in which effective alternative renal-replacement therapy is available, this guideline is not adequate to prevent HCV infection and thus exposes patients to unacceptable risks. The authors' figure of 5 percent for the prevalence of chronic hepatitis due to HCV after kidney transplantation is optimistically low. Lau et al. found that among 100 patients undergoing kidney transplantation, 18 were seropositive for HCV.  . .",
author = "King, {Paul D.} and Cobi Lidor and Vail, {Thomas P.} and Manikkam Suthanthiran and Strom, {Terry B.}",
year = "1994",
month = "12",
day = "22",
doi = "10.1056/NEJM199412223312514",
language = "English",
volume = "331",
pages = "1719--1720",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "25",

}

TY - JOUR

T1 - Renal transplantation

AU - King, Paul D.

AU - Lidor, Cobi

AU - Vail, Thomas P.

AU - Suthanthiran, Manikkam

AU - Strom, Terry B.

PY - 1994/12/22

Y1 - 1994/12/22

N2 - Suthanthiran and Strom (Aug. 11 issue)1 “discourage the use of organs from donors seropositive for the hepatitis C virus [HCV] for grafting in recipients who are seronegative for the virus.” In the setting of renal transplantation, in which effective alternative renal-replacement therapy is available, this guideline is not adequate to prevent HCV infection and thus exposes patients to unacceptable risks. The authors' figure of 5 percent for the prevalence of chronic hepatitis due to HCV after kidney transplantation is optimistically low. Lau et al. found that among 100 patients undergoing kidney transplantation, 18 were seropositive for HCV.  . .

AB - Suthanthiran and Strom (Aug. 11 issue)1 “discourage the use of organs from donors seropositive for the hepatitis C virus [HCV] for grafting in recipients who are seronegative for the virus.” In the setting of renal transplantation, in which effective alternative renal-replacement therapy is available, this guideline is not adequate to prevent HCV infection and thus exposes patients to unacceptable risks. The authors' figure of 5 percent for the prevalence of chronic hepatitis due to HCV after kidney transplantation is optimistically low. Lau et al. found that among 100 patients undergoing kidney transplantation, 18 were seropositive for HCV.  . .

UR - http://www.scopus.com/inward/record.url?scp=0028778825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028778825&partnerID=8YFLogxK

U2 - 10.1056/NEJM199412223312514

DO - 10.1056/NEJM199412223312514

M3 - Letter

C2 - 7969372

AN - SCOPUS:0028778825

VL - 331

SP - 1719

EP - 1720

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 25

ER -